Clinical Trial Search

Primary: Renal Function Assessed by Estimated Glomerular Filtartion Rate (eGFR) — 85.50; 80.26 mL/min/1.73m^2 — p=0.3013

Primary: Change From Baseline in Hemoglobin A1C at Week 20 — -1.10; -0.69 A1C (%) — p=<0.001

Primary: Part B: Percentage of Participants Who Achieved Complete Response (Complete Response Rate) Based on Investigator Assessment — 11.9; 16.6 Percentage of participants…

Primary: Retention Without Relapse to Heroin Addiction (Measured at Month 6) — 54; 16; 11 Participants

Primary: Percentage of Participants Achieving Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 86.7 percentage of participants

Primary: Summary of Visual Analog Scales (VAS) of Pain Intensity Change From Baseline by Treatment Group With Single Dose of Oxymorphone IR Tablet and Multiple Dose of…

Primary: Adjusted Percentage of Patients With Successful Overall Colon Preparation, Assessed by the Global Score of the Boston Bowel Preparation Scale (BBPS). — 97.18; 97.65…

Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 70.4; 1.3 percentage of…

Primary: Treatment Failure — 6; 3 Participants — p=0.3

Primary: Time to Last Unformed Stool (TLUS) — 44.3; 40.3 hours

Primary: Urinary Frequency — 10.5; 11; 12; 8.5 urinations

Primary: Progression Free Survival (PFS) by Investigator Assessment — 23.8; 13.0 Months — p=<0.0000001

Primary: Percentage of Participants With a ≥2 Point Improvement in Glabellar Line Scale (GLS) as Independently Assessed by Investigator and and Subject — 67.5; 1.2 percentage of…

Primary: Number of Participants With Successful Initiation of Treatment Within 4 Weeks of Randomization — 25; 17 Participants

Primary: Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12) — 92.2; 92.2 Percentage of participants — p=<0.001